Modern medicine has given us so many incredible advances to improve longevity and enhance quality of life. Unfortunately, the development of medical devices, also acts as a double-edged sword. While these devices provide us with the opportunity to save the life of a patient, they can also act as a reservoir for microorganisms and infections.
In recent decades we have seen a shift in health care and infection prevention to reduce the usage of these devices. Utilization rates are now a focus of efforts at a national level. Reduce the number of devices to reduce the risk of infection, is the mentality.
In the face of growing antimicrobial resistance
and the rise of medical tourism
extremely resistant organism are spreading. The latest report from the US Centers for Disease Control and Prevention (CDC) notes that each year in the United States, there are more than 2.8 million antibiotic-resistant infections and more than 35,000 people die as a result.
A new study
assessing data reported into the CDC’s National Healthcare Safety Network (NHSN)—which is where infection prevention and health care-associated data is reported by hospitals—found that resistant pathogens are found at a higher rate among those patients with device-associated infections.
Assessing data from 2015-2017 reported into NHSN, the study team reviewed central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated events (VAEs), and surgical site infections (SSIs). Infections from acute-care hospitals, long-term acute-care hospitals, and inpatient rehab facilities, were assessed.
This analysis focused on the percentage of pathogens with nonsusceptibility (%NS) to certain antibiotics and then calculated for each health care-associated infection type. After assessing the data from over 5600 hospitals, the majority of infections were a result of Escherichia coli
, Staphylococcus aureus
, and Klebsiella spp
The percentage of pathogens with nonsusceptibility was significantly higher in those patients with device-related health care-associated infections than those with surgical site infections. From the infection prevention perspective, this is relevant for several reasons. First, we know that invasive medical devices increase the risk for infections, but this helps reinforce the “do we really need this Foley catheter?” when it also brings the higher risk of resistant infections.
Second, since these are only infections associated with devices and surgeries, there’s little way to assess other infections related to medical devices, like peripheral IVs. Lastly, the surgeries that are reported into NHSN are limited and do not represent all surgical-site infections that might exist, so we can’t discount that those not reported might yield higher rates of drug-resistant infections.
While this study raises several questions, it drives home the importance of reducing utilization of medical devices as they inherently increase the risk of infections, especially those resistant ones.
Moreover, when use is absolutely necessary, it is important to closely monitor the susceptibility of any organism found growing and work closely with infectious disease physicians to guide smart antibiotic stewardship efforts. While advancements might improve patient outcomes, we must also consider the risk that such invasive medical devices create when employed.